HOME Research Insight Biosimilars Market Is Highly Consolidated with Top 3 Players such as Sandoz, Teva, and Hospira Occupying 90% Share



Biosimilars Market Is Highly Consolidated with Top 3 Players such as Sandoz, Teva, and Hospira Occupying 90% Share


The key players in the global biosimilars market are Sandoz (Germany), Hospira (U.S.), Teva (Israel), Dr. Reddyís Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), and Intas Biopharmaceultical Ltd. (India). Sandoz has emerged as the market leader in the global biosimilars market and is likely to maintain this leadership position in the coming years. Sandoz entered the biosimilars market in 2006 with the launch of Omnitrope (human growth hormone)-a biosimilar drug-in the European market. Sandozís biosimilar product offerings include Zarzio (G-CSF), Omnitrope (Human Growth Hormone), and Binocrit (epoeitin-alpha). Thus, a broad product portfolio enables the company to gain a competitive advantage over other players in the market. The company focuses on strengthening its market position by significantly investing in research and development activities. It has a robust biosimilar pipeline with about 10 drugs. Of all the biosimilars in the pipeline, four biosimilars are currently in the phase III trials (including monoclonal antibodies, a biosimilar version of the originator compound rituximab for the treatment of follicular lymphoma) and a biosimilar in phase II trial for rheumatoid arthritis. The other molecules undergoing phase III testing are biosimilar versions of peg-filgrastim and epoetin-alfa.

Teva, another major player, has the capability to provide stiff competition to Sandoz. In 2000, Teva entered the biosimilars market by setting up a clear long-term biosimilar strategy. Since then Teva has undergone several acquisitions and agreements with contract manufacturing organizations as well as various strategic alliances to strengthen its manufacturing unit and R&D capabilities. Tevaís alliance with Lonza Group in 2009 helped to generate significant opportunities for the company by developing, manufacturing, and marketing biosimilar drugs related to monoclonal antibodies and recombinant proteins. The companyís first biosimilar that received marketing authorization in the European Union was Tevagrastim (G-CSF) in 2007.

Extensive research in this market has brought to light that agreements, partnerships, strategic alliances, and collaborations together was found to be the key strategy followed by industry players. During 2010 to 2013, the industry witnessed 21 different agreements and collaborations by players. The major players involved in this section are Amgen, Inc. (U.S.), Biocon Ltd. (India), and Celltrion, Inc. (Korea). For instance, Biocon Ltd. entered into an agreement with Mylan, Inc. in February 2013 for the development and commercialization of generic versions of Bioconís three insulin analog products. The agreement helped both the companies to build a strong global presence in generic insulin analogs and provided affordable therapy options to physicians, healthcare providers, and diabetes patients, globally. Additionally, these companies invested significant amounts in R&D for biosimilars, especially monoclonal antibodies to treat cancer (oncology), autoimmune disorders, and infectious diseases. For instance, BioXpress has 16 MAbs in pipeline, while GeneTechno Science of Japan has 6 MAbs for different therapeutic areas. Other key products that have gained maximum attention from drug makers are insulin, interferons, filgrastim, erythropoietin, and follitropin.

Asia-Pacific is a lucrative destination for drug makers for establishing manufacturing plants and to undertake alliances with CMOs and CROs that respectively increase the production capacity and clinical trial activities of biosimilars. As a result, Asia-Pacific countries such as China, India, South Korea, and Australia has witnessed double digit growth rate by 2018.

Related Reports:

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports